Answers are grounded in this paper and cite their sources.
Primary sclerosing cholangitis is a rare hepatobiliary condition of unknown cause characterized by inflammation of the extrahepatic and intrahepatic bile ducts that causes focal narrowing, dilatation, or obliteration by local periductular fibrosis. This disease is one of the leading indications for liver transplantation in adults, because it usually progresses to cirrhosis, portal hypertension, and liver failure (1). Seventy-five percent of patients with sclerosing cholangitis have inflammatory bowel disease, especially ulcerative colitis (2). Sclerosing cholangitis has rarely been observed in children with immunodeficiency, histiocytosis X, cystic fibrosis, Alagille's syndrome, and celiac disease, reticulum cell sarcoma, and sickle cell anemia (3). Independent of the cause, there has been no satisfactory treatment (2). Drugs that have been ineffective have included D-penicillamine (4), corticosteroids (5), cyclosporine (6), methotrexate (7), and colchicine (5). Ursodeoxycholic acid has been associated with some improvement in clinical manifestations of primary sclerosing cholangitis in a few studies (8-10), but has not been effective in other studies (11,12). This report describes three children with sclerosing cholangitis and inflammatory bowel disease whose liver tests and symptoms improved when treated with oral vancomycin. CASE 1 The patient was a 15-year-old boy who had had colitis and sclerosing cholangitis for 2.5 years. In August 1993, he had diarrhea, a 20-lb weight loss, diffuse abdominal pain, and jaundice. Serum studies showed total bilirubin, 4.12 mg/dl; direct bilirubin, 1.8 mg/dl; aspartate aminotransferase, 261 IU/l; γ-glutamyl transpeptidase (GGT), 716 IU/l, and albumin, 2.7 g/dl. Results of examination of a liver biopsy specimen were consistent with sclerosing cholangitis with mixed polymorphonuclear neutrophils and lymphocytic infiltrate in the bile ducts and portal areas, proliferation of pseudoductules, and moderate portal fibrosis without bridging (Fig. 1A). An endoscopic retrograde cholangiopancreatographic (ERCP) study showed early sclerosing cholangitis with several intra- and extrahepatic strictures (Fig. 2A). Cultures of bile, small bowel, and colon revealed no pathogens. Colonoscopy with analysis of biopssy specimens showed diffuse, nonspecific, acute, and chronic colitis. From December 1993 to June 1994, he was intermittently treated with 250 mg oral vancomycin four times daily for stools that were persistently positive for Clostridium difficile toxin but negative for other pathogens. Diarrhea, anorexia, and abdominal pain resolved during vancomycin therapy, his eryhtrocyte sedimentation rate (ESR) and serum liver test results reached normal levels. Since June 1994, he was had continued therapy with 300 mg ursodeoxycholic acid twice daily and had multiple stool studies for C. difficile toxin, polymerase chain reaction for C. difficile, cultures, and examinations for ova and parasites that were negative for pathogens. Intermittently, he had symptoms including bloody diarrhea, abdominal pain, and anorexia associated with abnormal blood study results (ESR, GGT, and alanine aminotransferase [ALT]) and was given multiple treatments of oral vancomycin (Fig. 3). His symptoms and blood test results normalized during vancomycin therapy and worsened within 2 to 4 weeks after vancomycin was discontinued (Fig. 4). Compared with the liver biopsy specimens obtained during cessation of vancomycin therapy, the specimens obtained during vancomycin therapy demonstrated less portal inflammation and portal fibrosis (Fig. 1B). An ERCP study performed during vancomycin therapy revealed a normal biliary tract (Fig. 2B). More recently, symptoms and abnormal laboratory test results were treated with oral metronidazole or ciprofloxacin instead of oral vancomycin. There were no changes in symptoms or laboratory test findings during administration of these antibiotics.FIG. 1: Specimens from liver biopsies performed in patient in case 1 before oral vancomycin therapy (A) and after oral vancomycin therapy (B) (hematoxylin-eosin, magnification ×100). Liver biopsy specimens show significantly less focal bridging fibrosis and portal inflammation after oral vancomycin treatment (B) compared with that in the specimens obtained before treatment (A).FIG. 2: An endoscopic retrograde cholangiopancreatographic study performed in the patient in case 1 before oral vancomycin therapy showing (arrows) biliary strictures (A) and after oral vancomycin therapy showing (arrows) biliary strictures are no longer present (B).FIG. 3: The effects of multiple treatments of oral vancomycin on the blood studies (ALT, GGT, ESR) in Case 1 are shown.FIG. 4: The effects of oral vancomycin on blood studies (GGT, ESR, ALT) of three children with inflammatory bowel disease and sclerosing cholangitis are shown.CASE 2 A 14-year-old girl had Crohn's disease of the large and small bowel and sclerosing cholangitis. At age 5 years, she had had bloody diarrhea and showed severe colitis on colonoscopy and skip lesions in the duodenum and small bowel in an upper gastrointestinal series. At age 8 years, she had an elevated serum GGT concentration of 1351 IU/l, and analysis of a liver biopsy specimen showed portal fibrosis and bile ductular proliferation consistent with sclerosing cholangitis. An ERCP showed mild intrahepatic and extrahepatic bile duct narrowing that was indicative of early sclerosing cholangitis. During the past 6 years, she has been maintained on 50 mg 6-mercaptopurine daily, 500 mg sulfasalazine three times daily, and 300 mg ursodeoxycholic acid three times daily. For 5 years until May 1995, the GGT level ranged from 59 to 286 IU/l and the ESR from 18 to 60 mm/hr. From May 1995, until oral vancomycin therapy was begun in August 1995, she had bloody diarrhea, right upper quadrant abdominal pain without fever or tenderness, and abnormal blood test results with GGT, 468 to 818 IU/l; ALT 57 to 84 IU/l; and ESR, 60 to 103 mm/hr. In July 1995, abdominal ultrasound showed a dilated common bile duct (6 mm in diameter). Before vancomycin therapy was initiated, stool cultures, C. difficile toxin, and examination for ova and parasites were negative. During therapy with 125 mg vancomycin three times daily for 3 months beginning in August 1995, GGT, ALT, and ESR decreased to near normal values (Fig. 4). Within 2 weeks after introduction of vancomycin, she became asymptomatic with normal findings in abdominal ultrasound (4 mm diameter of bile duct). For the 6 months after treatment with oral vancomycin and while continuing therapy with 6-mercaptopurine, sulfasalazine, and ursodeoxycholic acid, she was asymptomatic. However, during the past year she has been poorly compliant with pharmacologic therapy and has had recurrence of right upper quadrant abdominal pain with elevation of ESR, ALT, and GGT, which have not responded to oral vancomycin treatment. CASE 3 A 14-year-old boy with Crohn's disease of the stomach, small bowel, and colon and sclerosing cholangitis. At age 11 years, he had bloody diarrhea, weight loss, and abnormal findings in liver tests (GGT 291 IU/l and ALT 206 IU/l). Endoscopic studies showed severe acute and chronic inflammation of the entire colon, antrum, and duodenum. Findings in analysis of a liver biopsy specimen were consistent with sclerosing cholangitis, showing proliferation and large bile ducts with intense lymphoplasmacytic infiltrate and fibrous tissue surrounding the bile ducts. He did not undergo an ERCP study. He was steroid dependent and had abdominal cramping pain, nausea, and bloody diarrhea if his prednisone dose was decreased below 15 mg daily. He was maintained with 75 mg 6-mercaptopurine daily for 2 years. During the past year, before vancomycin therapy was begun, his GGT ranged from 350 to 1189 IU/l, ALT from 49 to 499 IU/l, and ESR from 19 to 84 mm/hr. During therapy with 250 mg oral vancomycin three times daily for 2 weeks and then twice daily for 4 weeks, he remained asymptomatic while therapy with prednisone, which had initially been prescribed at 40 mg daily, was tapered. His GGT, ALT, and ESR levels became normal (Fig. 4). For the 6 months of vancomycin and steroid therapy, while continuing 6-mercaptopurine, he was asymptomatic and had normal levels of ESR, ALT, and GGT. In September 1996, he had bloody diarrhea, abdominal pain, and vomiting for 2 weeks associated with an increase in ALT to 130 IU/l, GGT to 148 IU/l, and ESR to 55 mm/hr. Stool cultures and C. difficile toxin revealed no pathogens. Within 24 hours after 250 mg oral vancomycin was administered (three times daily), he became asymptomatic and within 6 weeks his ALT, GGT, and ESR readings were normal. For the past 14 months, he has been asymptomatic with normal levels of ALT, GGT, and ESR. DISCUSSION The causes of inflammatory bowel disease and sclerosing cholangitis are unknown. Infectious mechanisms have been proposed, but there have been no specific infectious agents identified. Many antibiotics have been tried, but none have been effective (2). Oral vancomycin has not been previously used in the treatment of sclerosing cholangitis or inflammatory bowel disease. Vancomycin is bactericidal for staphylococci, streptococci including enterococci, diphtheroids, Listeria monocytogenes, and species of clostridium, lactobacillus, Actinomyces, and bacillus. It is not active against Gram-negative bacilli, mycobacteria, or fungi. Vancomycin is poorly absorbed after oral administration (13). Enteric bacterial infection has been considered a cause of primary sclerosing cholangitis. In one study, investigators reported portal bacteremia in patients with ulcerative colitis who had colonic surgery (14). However, others did not find portal vein phlebitis, a typical feature of portal bacteremia, in most patients with primary sclerosing cholangitis (15). Because lithocholic acid, a hepatotoxic bile acid, is generated by intestinal flora, primary sclerosing cholangitis may be caused by abnormal production of toxic bile acids by gut flora (16). However, the composition and concentrations of bile acids have been normal in the bile and portal blood of patients with sclerosing cholangitis and inflammatory bowel disease (17). Animal studies have provided evidence that enteric bacteria produce toxic proinflammatory agents, such as N-formylmethionyl peptides, which can be absorbed, enter the enterohepatic circulation, and appear undegraded in the bile, which causes periportal inflammation and hepatocyte damage (18). In addition, a ubiquitous bacterial cell wall polymer, peptidoglycan-polysaccharide, has been shown in a rat model of bacterial overgrowth to play a role in causing hepatobiliary disease that resembles primary sclerosing cholangitis (19). From these data, we can hypothesize that oral vancomycin may kill the enteric bacteria that produce these biliary toxic inflammatory agents that are absorbed. The recurrence of symptoms and abnormal laboratory findings observed in these patients after vancomycin was discontinued suggests that the antibiotic did not completely eradicate the infection or that there was reinfection. Further, prospective studies will be necessary before the indications, dosage, length of time for treatment, and potential long-term benefits of oral vancomycin can be determined.
No takes yet. Share an insight, caveat, or question.
Cox et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: